Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intellikine Inc.

Division of Takeda Pharmaceutical Co. Ltd.
www.intellikine.com

Latest From Intellikine Inc.

Infinity Gets More Than A Cash Boost With AbbVie Tie-Up

In a deal worth more than $800 million, AbbVie injects a vote of confidence into Infinity’s late-stage PI3K inhibitor program, but leaves the biotech the freedom to conduct other partnerships.

BioPharmaceutical Clinical Trials

Orteronel Leaves Hole In Millennium/Takeda Pipeline

The non-steroidal androgen synthesis inhibitor failed to show a survival benefit in chemotherapy-naïve prostate cancer patients after also failing in post-chemo patients in 2013. With Takeda ending development of the Phase III candidate, its Millennium cancer pipeline is reduced to a pair of Phase III candidates.

BioPharmaceutical Clinical Trials

Orteronel Leaves Hole In Millennium/Takeda Pipeline

The non-steroidal androgen synthesis inhibitor failed to show a survival benefit in chemotherapy-naïve prostate cancer patients after also failing in post-chemo patients in 2013. With Takeda ending development of the Phase III candidate, its Millennium cancer pipeline is reduced to a pair of Phase III candidates.

BioPharmaceutical Japan

Orteronel Leaves Hole In Millennium/Takeda Pipeline

The non-steroidal androgen synthesis inhibitor failed to show a survival benefit in chemotherapy-naïve prostate cancer patients after also failing in post-chemo patients in 2013. With Takeda ending development of the Phase III candidate, its Millennium cancer pipeline is reduced to a pair of Phase III candidates.

BioPharmaceutical Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Troy Wilson, PhD, Pres. & CEO
    Christian Rommel, PhD, CSO
    Heidi Henson, Dir., Fin.
  • Contact Info
  • Intellikine Inc.
    Phone: (858) 768-6500
    10931 N. Torrey Pines Rd.
    Ste. 103
    La Jolla, CA 92037
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register